Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosiss

L Mettler, Mettler L, H. Steinmüller, Steinmüller H, E. Schachner-Wünschmann, Schachner-Wünschmann E
Human Reproduction · 1991 · vol. 6(5) , pp. 694–698 · doi:10.1093/oxfordjournals.humrep.a137410 · PMID:1834693 · W2162849795
article OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Depot GnRH-agonist Zoladex treatment of 80 women with genital endometriosis resulted in objective improvement, symptom relief, and reduced hormone levels, with minimal side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Eighty patients with different stages of genital endometriosis were treated with Zoladex, a gonadotrophin-releasing hormone analogue in a depot formulation, injected subcutaneously every 4 weeks. The stages of endometriosis (I-IV) were classified according to the revised American Fertility Society recommendations (AFS criteria) via pelviscopy before and after 6 months of treatment. Fifty-eight second-look pelviscopies were performed with the following objective changes after (before) treatment: Stage IV 0 (3); Stage III, 2 (13); Stage II, 12 (30); Stage I, 19 (12). Twenty-five patients presented with Stage 0 after therapy and were healed. All 57 symptomatic patients showed a subjective response to Zoladex therapy with a significant decrease of the total pelvic symptom score. Thirty-eight patients with infertility wished to become pregnant and so far 16 (40%) have conceived. During therapy, the serum concentrations of luteinizing hormone, follicle stimulating hormone, estradiol and progesterone were significantly suppressed. All patients were amenorrhoeic after 1-2 injections. Restoration of ovarian function with resumption of menstruation occurred within 57-92 days after the last injection of Zoladex (1-2 months after end of treatment). Side-effects were minimal and were those expected of the hypo-oestrogenic state, such as hot flushes, vaginal dryness and decrease of libido.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Buserelin Endometriosis Adult Buserelin Buserelin Buserelin Buserelin Delayed-Action Preparations Endometriosis Endometriosis Endometriosis Estradiol Estradiol Female Goserelin Humans Luteinizing Hormone Luteinizing Hormone Pregnancy Pregnancy Outcome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (10)

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00
openalex
last seen: 2026-05-11T06:01:13.017405+00:00
pubmed
last seen: 2026-05-13T22:12:00.397535+00:00
License: CC0 · commercial use OK